Company · Ownership research

Kymera Therapeutics, Inc. KYMR

CIK 0001815442

Form 4 transactions dated Nov 1, 2023 to Nov 11, 2026, as reported to the SEC.

Insider trading Initial holdings Institutional holders

This page lists 30 of 31 rows; the complete set is available through the API.

Insider filings on file run through Oct 1, 2026.

Some filings are submitted jointly by several insiders. The SEC form does not apportion the reported figures between them, so results include every joint filer.

Insider purchases & sales

Purchased: $220.60M
Sold: $543.75M

Nov 1, 2023 – Oct 1, 2026
Available records · partial months are marked ·

Insiders in this window

202410 of 30 preview events · 31 available in 2024

Date	Insider	Activity	Trade value (USD)	% of prior holding
Dec 2, 2024	Esposito Pamela Director	Sale10b5-1 footnote	$122.50K 2,500 shares sold	100.00% sold Direct holding	▾
Sep 17, 2024	Esposito Pamela Director	Sale10b5-1 footnote	$651.77K 13,500 shares sold	100.00% sold Direct holding	▾
Aug 26, 2024	Albers Jeffrey W. Director	Sale10b5-1 footnote	$245.51K 5,000 shares sold	100.00% sold Direct holding	▾
Aug 20, 2024	BAKER JULIAN · BAKER FELIX · BAKER BROS. ADVISORS LP · Baker Brothers Life Sciences LP · 667, L.P. · Baker Bros. Advisors (GP) LLC Director	Purchase	$46.41 1 shares bought	Unavailable Indirect holding	▾
Jul 16, 2024	Gollob Jared Chief Medical Officer	Sale10b5-1 footnote	$1.06M 23,145 shares sold	Unavailable Direct holding	▾
Jul 15, 2024	Gollob Jared Chief Medical Officer	Sale10b5-1 footnote	$742.93K 16,455 shares sold	14.67% sold Direct holding	▾
Jul 9, 2024	Booth Bruce Director	Sale10b5-1 footnote	$17.35M 453,960 shares sold	Unavailable Indirect holding	▾
Jun 13, 2024	Booth Bruce Director	Sale10b5-1 footnote	$356.80K 10,200 shares sold	Unavailable Indirect holding	▾
Jun 12, 2024	Booth Bruce Director	Sale10b5-1 footnote	$593.38K 16,740 shares sold	Unavailable Indirect holding	▾
Jun 7, 2024	Horobin Joanna Director	Sale10b5-1 footnote	$280.40K 8,500 shares sold	100.00% sold Direct holding	▾

Showing 30 / 31 record groups in 2024. The complete set is available through the API.

Kymera Therapeutics, Inc. · KYMR

Follow the people behind the trades.

Log in to look up the full history beyond 3 years, use advanced screening & filtering, download CSV, and reach other datasets through the Akkru API.

Download CSV
Earlier filings
Advanced screening & filtering
API & AI access

Already have an account?

＋ New accounts get free API credits to explore data beyond ownership filings.

For AI agents & developers

The initial HTML of this page carries its exact data as script#research-data (JSON): values, units, scope, preview limits and SEC sources. Read it directly, no script or API key needed; script#research-access says what needs an account. For the year shown, this page lists 30 of 31 purchase / sale groups and 30 of 58 other groups; the totals and the monthly series cover the whole window.

Without an account: the last 3 years, with the row caps stated on the page. A free account opens all history on file on these pages and the CSV of what a page shows. Rows beyond the caps and bulk retrieval go through the authenticated API / MCP / CLI.

MCP  https://api.akkrudata.ai/mcp

akkru_insider_transactions
{"action":"list","ticker":"KYMR","transaction_code":["P","S"],"transaction_form_type":"4","page_size":20}

Connect to MCP with OAuth and follow the returned pagination. Credits and usage limits depend on the account.

MCP endpoint: https://api.akkrudata.ai/mcp
API / MCP / CLI documentation: /documents
llms.txt: /llms.txt

Sources, coverage & how to read this data

Figures are as reported to the SEC and merged with later amendments where Akkru could match them. Preview limits apply to what is listed, not to the totals, which come from the complete reported data. Nothing is zero-filled: a missing quarter or month is shown as missing.

Non-cancelled, non-derivative purchase (P) and sale (S) rows dated inside the public window, as reported. Share totals are on today's split-adjusted basis. Includes open-market and private transactions. Data after the latest filing is not asserted complete and is not zero-filled. A grouped event shares filing, transaction date, security, code, direction, ownership bucket and source. Derivative groups also match underlying security, exercise price, exercise/expiration dates and footnote references. Reported rows are retained; P/S price lots can be grouped. Post-transaction balances are never summed.